logo
Book a meeting
CeleCor Therapeutics

Cele Cor Therapeutics

Biotechnology, 1155 Camino Del Mar, Del Mar, California, 92014, United States, 1-10 Employees

celecor.com

  • LinkedIn

phone no Phone Number: 85********

Who is CELECOR THERAPEUTICS

Were a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital ...

Read More

lock icon Get Full Access
map
  • 1155 Camino Del Mar, Del Mar, California, 92014, United States Headquarters: 1155 Camino Del Mar, Del Mar, California, 92014, United States
  • 2017 Date Founded: 2017
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CELECOR THERAPEUTICS

CeleCor Therapeutics Org Chart and Mapping

Employees
Oana Cociorva

Oana Cociorva

Sr. Director, Corporate Planning and Administration

See Full Org Chart arrow
email-formate-icon
View Email Formats for CeleCor Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding CeleCor Therapeutics

Answer: CeleCor Therapeutics's headquarters are located at 1155 Camino Del Mar, Del Mar, California, 92014, United States

Answer: CeleCor Therapeutics's phone number is 85********

Answer: CeleCor Therapeutics's official website is https://celecor.com

Answer: CeleCor Therapeutics's revenue is Under $1 Million

Answer: CeleCor Therapeutics's SIC: 8731

Answer: CeleCor Therapeutics's NAICS: 541714

Answer: CeleCor Therapeutics has 1-10 employees

Answer: CeleCor Therapeutics is in Biotechnology

Answer: CeleCor Therapeutics contact info: Phone number: 85******** Website: https://celecor.com

Answer: Were a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital therapies, because early action is crucial to preserve heart muscle. The longer a coronary artery is closed, the more severe the damage to the heart. Starting treatment before patients reach the hospital, significantly improves the chances of a positive outcome. Were developing zalunfiban; a prompt, potent, and predictable medication designed for treating patients with a heart attack before they reach the hospital. Zalunfiban has the potential to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care. Were currently running the CeleBrate trial: a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter, study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access